115 related articles for article (PubMed ID: 28915580)
1. Molecular and functional characterization of a new 3' end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant Imatinib.
Perfetti V; Laurini E; Aulić S; Fermeglia M; Riboni R; Lucioni M; Dallera E; Delfanti S; Pugliese L; Latteri FS; Pietrabissa A; Pricl S
Oncotarget; 2017 Aug; 8(34):56158-56167. PubMed ID: 28915580
[TBL] [Abstract][Full Text] [Related]
2. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).
Duensing A; Medeiros F; McConarty B; Joseph NE; Panigrahy D; Singer S; Fletcher CD; Demetri GD; Fletcher JA
Oncogene; 2004 May; 23(22):3999-4006. PubMed ID: 15007386
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course.
Lasota J; Dansonka-Mieszkowska A; Stachura T; Schneider-Stock R; Kallajoki M; Steigen SE; Sarlomo-Rikala M; Boltze C; Kordek R; Roessner A; Stachura J; Miettinen M
Mod Pathol; 2003 Dec; 16(12):1257-64. PubMed ID: 14681327
[TBL] [Abstract][Full Text] [Related]
5. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK
Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563
[TBL] [Abstract][Full Text] [Related]
6. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics.
Miettinen M; Lasota J
Pol J Pathol; 2003; 54(1):3-24. PubMed ID: 12817876
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
[TBL] [Abstract][Full Text] [Related]
9. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Rubin BP; Singer S; Tsao C; Duensing A; Lux ML; Ruiz R; Hibbard MK; Chen CJ; Xiao S; Tuveson DA; Demetri GD; Fletcher CD; Fletcher JA
Cancer Res; 2001 Nov; 61(22):8118-21. PubMed ID: 11719439
[TBL] [Abstract][Full Text] [Related]
10. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
Haller F; Detken S; Schulten HJ; Happel N; Gunawan B; Kuhlgatz J; Füzesi L
Ann Surg Oncol; 2007 Feb; 14(2):526-32. PubMed ID: 17139461
[TBL] [Abstract][Full Text] [Related]
11. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
[TBL] [Abstract][Full Text] [Related]
12. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.
Taniguchi M; Nishida T; Hirota S; Isozaki K; Ito T; Nomura T; Matsuda H; Kitamura Y
Cancer Res; 1999 Sep; 59(17):4297-300. PubMed ID: 10485475
[TBL] [Abstract][Full Text] [Related]
13. Secondary resistance to imatinib in patients with gastrointestinal stromal tumors through an acquired KIT exon 17 mutation.
Wang CM; Fu H; Zhao GF; Zhou XY; Du CY; Dong RZ; Zhou Y; Shi YQ
Mol Med Rep; 2009; 2(3):455-60. PubMed ID: 21475850
[TBL] [Abstract][Full Text] [Related]
14. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Lasota J; Miettinen M
Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
[TBL] [Abstract][Full Text] [Related]
16. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.
Lux ML; Rubin BP; Biase TL; Chen CJ; Maclure T; Demetri G; Xiao S; Singer S; Fletcher CD; Fletcher JA
Am J Pathol; 2000 Mar; 156(3):791-5. PubMed ID: 10702394
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature.
Ito T; Yamamura M; Hirai T; Ishikawa T; Kanda T; Nakai T; Ohkouchi M; Hashikura Y; Isozaki K; Hirota S
Int J Clin Exp Pathol; 2014; 7(11):8024-31. PubMed ID: 25550846
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic targets in gastrointestinal stromal tumors].
Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal stromal tumours.
Connolly EM; Gaffney E; Reynolds JV
Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
[TBL] [Abstract][Full Text] [Related]
20. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors.
Wardelmann E; Losen I; Hans V; Neidt I; Speidel N; Bierhoff E; Heinicke T; Pietsch T; Büttner R; Merkelbach-Bruse S
Int J Cancer; 2003 Oct; 106(6):887-95. PubMed ID: 12918066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
